A new treatment for dengue using combined antibodies
A Novel Cost-Effective Multispecific Therapeutic for Dengue
This study is working on a new treatment for dengue fever that combines two powerful antibodies into one, making it stronger and easier to produce, so it can help kids and others affected by the disease feel better with a smaller dose.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mapp Biopharmaceutical, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11185642 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic approach for dengue, a serious mosquito-borne disease. The project aims to create a multi-specific antibody-derived treatment that combines the effectiveness of two neutralizing antibodies into a single, longer-lasting molecule. This innovative therapy is designed to be more potent, requiring a lower dose, and can be manufactured efficiently. By targeting the disease in a cost-effective manner, the research seeks to provide a viable treatment option for affected individuals, especially children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years, especially those who may not have access to existing vaccination options.
Not a fit: Patients who are older than 11 years or those who have already received the dengue vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safe and effective treatment for dengue, particularly benefiting young patients who are currently at risk.
How similar studies have performed: Other research has shown promise in developing antibody-based therapies for infectious diseases, indicating potential success for this novel approach.
Where this research is happening
San Diego, United States
- Mapp Biopharmaceutical, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Maamary, Jad — Mapp Biopharmaceutical, INC.
- Study coordinator: Maamary, Jad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.